Used in pharmaceutical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), this compound shows promise in the treatment of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. By blocking BTK activity, it modulates B-cell receptor signaling, reducing the activation of immune cells involved in inflammatory responses. It is also being investigated for oncology applications, particularly in B-cell malignancies like chronic lymphocytic leukemia and mantle cell lymphoma, where BTK plays a key role in cancer cell survival and proliferation. Its structural design allows for improved selectivity and reduced off-target effects, making it a candidate for oral administration in long-term therapies.